For the Inventor, By the Inventor

Enter assignee name

Eligo Bioscience

USPTO Granted Patents = 39

EPO Patents = 4

Forward Citations = 30

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Antoine Decrulle (24 out of 24 patents)

Jesus Fernandez Rodriguez (24 out of 24 patents)

Xavier Duportet (22 out of 23 patents)

4. Aymeric Leveau (10 out of 10 patents)

5. Inès Canadas Blasco (10 out of 10 patents)

6. Aurélie Mathieu (10 out of 10 patents)

7. David Bikard (6 out of 21 patents)

8. Cristina Del Carmen Gil-Cruz (5 out of 5 patents)

9. Christian Ivan Pérez-Shibayama (5 out of 5 patents)

10. Burkhard Ludewig (5 out of 5 patents)

11. Andreas Brodel (4 out of 4 patents)

12. Thibault Carlier (4 out of 4 patents)

13. Igor Stzepourginski (3 out of 3 patents)

14. Lun Cui (2 out of 2 patents)

15. Antonina Krawczyk (2 out of 2 patents)

Core Competencies:

Chimeric Receptor Binding Proteins

Phage-Derived Particles

DNA Payload Delivery

Microbiome Modulation

Engineered Postbiotics

Bacterial Delivery Vehicles

Transcriptional Control

Sequence-Specific Antimicrobials

Lytic Phages

Gene Therapy

Cosmetic Applications

Bacteriocins

39 patents: Sort by Forward Citations

1. 12729223 - CHIMERIC RECEPTOR BINDING PROTEINS FOR USE IN BACTERIAL DELIVERY VEHICLES (2026-09-08),

2. 12460216 - Phage-derived particles for in situ delivery of DNA payload into C. acnes population (2025-11-04),

3. 12454696 - recombinant phages encoding a human protein (2025-10-28),

4. 12414962 - Method for treatingbacteria-associated diseases (2025-09-16),

5. 12214070 - Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins (2025-02-04),

6. 12214022 - Sequence-specific antimicrobials by blocking DNA repair (2025-02-04),

7. 12098372 - Microbiome modulation of a host by delivery of DNA payloads with minimized spread (2024-09-24),

8. 11970716 - Transcriptional control in prokaryotic cells using DNA-binding repressors (2024-04-30),

9. 11970701 - Phage-derived particles for in situ delivery of DNA payload intopopulation (2024-04-30),

10. 11952595 - Production of lytic phages (2024-04-09),

11. 11952594 - Pharmaceutical compositions comprising bacterial delivery vehicles and uses thereof (2024-04-09),

12. 11946056 - Optimized vector for delivery in microbial populations (2024-04-02),

13. 11939598 - Production bacterial cells and use thereof in production methods (2024-03-26),

14. 11905516 - Optimized vector for delivery in microbial populations (2024-02-20),

15. 11840695 - Recombinantphages comprising transgenes (2023-12-12),

Eligo Bioscience is a biotechnology company based in Paris, France, specializing in the development of precision medicines that harness the power of synthetic biology. The company focuses on creating innovative therapeutic solutions that target specific bacteria in the human microbiome, aiming to address various health conditions. By leveraging advanced genetic engineering techniques, Eligo Bioscience is at the forefront of transforming microbiome research into practical applications for improved patient outcomes.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Eligo Bioscience

39 Patents

#153 in Paris

#585 in France

#17,428 in the World

Eligo Bioscience

Forward Citations = 30

17 inventors:

Antoine Decrulle (24 out of 24 patents)

Jesus Fernandez Rodriguez (24 out of 24 patents)

Xavier Duportet (22 out of 23 patents)

4. Aymeric Leveau (10 out of 10 patents)

5. Inès Canadas Blasco (10 out of 10 patents)

Please report any incorrect information to [email protected]

Loading…